Andrew Blauvelt
Advanced in Vitiligo

Dr. Andrew Blauvelt

Dermatology
James W. Baker MD LLC
9495 SW Locust St Ste A, 
Portland, OR 
Advanced in Vitiligo
James W. Baker MD LLC
9495 SW Locust St Ste A, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Blauvelt is a Dermatologist in Portland, Oregon. Dr. Blauvelt is rated as an Advanced provider by MediFind in the treatment of Vitiligo. His top areas of expertise are Plaque Psoriasis, Psoriasis, Atopic Dermatitis, and Actinic Keratosis.

His clinical research consists of co-authoring 308 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Vitiligo.

Specialties
Dermatology
Licenses
Dermatology in OR
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Moda Health
  • EPO
  • PPO

Locations

James W. Baker MD LLC
9495 SW Locust St Ste A, Portland, OR 97223
Call: 503-445-2200

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Decreasing Resident Memory T Cells While Increasing Clinical Durability: Higher Induction Doses of Risankizumab for Moderate-to-severe Plaque Psoriasis
Decreasing Resident Memory T Cells While Increasing Clinical Durability: Higher Induction Doses of Risankizumab for Moderate-to-severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: October 24, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
Enrollment Status: Completed
Publish Date: November 10, 2022
Intervention Type: Drug
Study Drug: Apremilast
Study Phase: Phase 4
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Enrollment Status: Completed
Publish Date: September 25, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
View 11 Less Clinical Trials

308 Total Publications

Moderate-to-severe atopic dermatitis and systemic corticosteroids are associated with insulin resistance and metabolic syndrome.
Moderate-to-severe atopic dermatitis and systemic corticosteroids are associated with insulin resistance and metabolic syndrome.
Journal: JAAD international
Published: December 16, 2025
View All 308 Publications
Similar Doctors
Advanced in Vitiligo
Dr. Maeran Landers
Dermatology
Advanced in Vitiligo
Dr. Maeran Landers
Dermatology

Advanced Dermatology Of Oregon PC

19255 SW 65th Ave Ste 260, 
Tualatin, OR 
 (5.4 miles away)
503-692-1212
Languages Spoken:
English
See accepted insurances

Maeran Landers is a Dermatologist in Tualatin, Oregon. Dr. Landers is rated as a Distinguished provider by MediFind in the treatment of Vitiligo. Her top areas of expertise are Atopic Dermatitis, Actinic Keratosis, Seborrheic Keratosis, and Warts.

Experienced in Vitiligo
Dr. Janelle Rohrback
Dermatology
Experienced in Vitiligo
Dr. Janelle Rohrback
Dermatology

Providence St Vincent Heart Clinics Cardiology Portland Clinic Beavert

15950 SW Millikan Way, 
Beaverton, OR 
 (4.5 miles away)
503-646-0161
Languages Spoken:
English
See accepted insurances

Janelle Rohrback is a Dermatologist in Beaverton, Oregon. Dr. Rohrback is rated as an Advanced provider by MediFind in the treatment of Vitiligo. Her top areas of expertise are Actinic Keratosis, Warts, Seborrheic Keratosis, and Sunburn.

Experienced in Vitiligo
Dr. Stephen Mannino
Dermatology
Experienced in Vitiligo
Dr. Stephen Mannino
Dermatology

Providence St Vincent Heart Clinics Cardiology Portland Clinic

800 SW 13th Ave, 
Portland, OR 
 (6.6 miles away)
503-221-0161
Languages Spoken:
English
See accepted insurances

Stephen Mannino is a Dermatologist in Portland, Oregon. Dr. Mannino is rated as a Distinguished provider by MediFind in the treatment of Vitiligo. His top areas of expertise are Actinic Keratosis, Seborrheic Keratosis, Warts, and Melanoma.

VIEW MORE VITILIGO DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Blauvelt's expertise for a condition
ConditionClose
  • Elite
  • Actinic Keratosis
    Dr. Blauvelt is
    Elite
    . Learn about Actinic Keratosis.
    See more Actinic Keratosis experts
  • Atopic Dermatitis
    Dr. Blauvelt is
    Elite
    . Learn about Atopic Dermatitis.
    See more Atopic Dermatitis experts
  • Plaque Psoriasis
    Dr. Blauvelt is
    Elite
    . Learn about Plaque Psoriasis.
    See more Plaque Psoriasis experts
  • Psoriasis
    Dr. Blauvelt is
    Elite
    . Learn about Psoriasis.
    See more Psoriasis experts
    • Advanced
    • Hypomelanotic Disorder
      Dr. Blauvelt is
      Advanced
      . Learn about Hypomelanotic Disorder.
      See more Hypomelanotic Disorder experts
    • Vitiligo
      Dr. Blauvelt is
      Advanced
      . Learn about Vitiligo.
      See more Vitiligo experts
    • Experienced
    • Alopecia Areata
      Dr. Blauvelt is
      Experienced
      . Learn about Alopecia Areata.
      See more Alopecia Areata experts
    • Autosomal Recessive Hypotrichosis
      Dr. Blauvelt is
      Experienced
      . Learn about Autosomal Recessive Hypotrichosis.
      See more Autosomal Recessive Hypotrichosis experts
    • Cicatricial Pemphigoid
      Dr. Blauvelt is
      Experienced
      . Learn about Cicatricial Pemphigoid.
      See more Cicatricial Pemphigoid experts
    • Contact Dermatitis
      Dr. Blauvelt is
      Experienced
      . Learn about Contact Dermatitis.
      See more Contact Dermatitis experts
    • Ecthyma
      Dr. Blauvelt is
      Experienced
      . Learn about Ecthyma.
      See more Ecthyma experts
    • Folliculitis
      Dr. Blauvelt is
      Experienced
      . Learn about Folliculitis.
      See more Folliculitis experts
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.